Published in Oncoimmunology on November 04, 2013
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell (2017) 1.40
Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol (2015) 0.96
Consensus nomenclature for CD8(+) T cell phenotypes in cancer. Oncoimmunology (2015) 0.94
Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clin Cancer Res (2015) 0.88
Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. J Immunol (2013) 0.86
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model. J Vis Exp (2015) 0.79
Preventing tumor escape by targeting a post-proteasomal trimming independent epitope. J Exp Med (2016) 0.78
CD8 engineered cytotoxic T cells reprogram melanoma tumor environment. Oncoimmunology (2015) 0.78
Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget (2016) 0.77
Tumor-associated fibroblasts predominantly come from local and not circulating precursors. Proc Natl Acad Sci U S A (2016) 0.76
Tumour ischaemia by interferon-γ resembles physiological blood vessel regression. Nature (2017) 0.75
In Vivo Imaging Sheds Light on Immune Cell Migration and Function in Cancer. Front Immunol (2017) 0.75
Development of novel murine mammary imaging windows to examine wound healing effects on leukocyte trafficking in mammary tumors with intravital imaging. Intravital (2016) 0.75
A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. Breast Cancer (Auckl) (2015) 0.75
Long-term intravital imaging of the multicolor-coded tumor microenvironment during combination immunotherapy. Elife (2016) 0.75
Rethinking the role of myeloid-derived suppressor cells in adoptive T-cell therapy for cancer. Oncoimmunology (2014) 0.75
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A (1993) 22.33
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Membrane vesicles as conveyors of immune responses. Nat Rev Immunol (2009) 14.72
Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res (1989) 12.85
Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol (2006) 12.29
Stromal fibroblasts in cancer initiation and progression. Nature (2004) 11.69
An improved cyan fluorescent protein variant useful for FRET. Nat Biotechnol (2004) 10.24
Shedding microvesicles: artefacts no more. Trends Cell Biol (2009) 8.84
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 8.72
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res (2004) 7.56
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol (2005) 6.05
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer (2006) 5.60
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle (2006) 4.67
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev (2008) 4.36
Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature (1988) 3.82
Mouse in red: red fluorescent protein expression in mouse ES cells, embryos, and adult animals. Genesis (2004) 3.80
No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet (2008) 3.32
Dynamic imaging of the immune system: progress, pitfalls and promise. Nat Rev Immunol (2006) 3.31
Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A (2008) 3.27
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15
Cross-presentation by intercellular peptide transfer through gap junctions. Nature (2005) 3.03
In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med (2007) 2.89
Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J Immunol (1996) 2.70
Inhibition of tumor growth by elimination of granulocytes. J Exp Med (1995) 2.65
Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc Natl Acad Sci U S A (1986) 2.63
Bystander elimination of antigen loss variants in established tumors. Nat Med (2004) 2.53
Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest (2008) 2.52
Fluorescent protein spectra. J Cell Sci (2001) 2.49
Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med (2006) 2.43
Direct labeling and visualization of blood vessels with lipophilic carbocyanine dye DiI. Nat Protoc (2008) 2.29
Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell (2013) 2.18
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity (2002) 2.18
Acute inflammation. A review. Am J Pathol (1977) 2.06
Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev (2008) 2.00
A transparent access chamber for the rat dorsal skin fold. Microvasc Res (1979) 1.98
Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci U S A (1995) 1.94
Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks. Nat Methods (2010) 1.88
Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med (1992) 1.81
IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest (2008) 1.71
Noninvasive visualization of tumors in rodent dorsal skin window chambers. Nat Biotechnol (1999) 1.69
In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci U S A (2007) 1.65
Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res (2008) 1.39
Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol (1995) 1.39
Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother (2004) 1.35
Recent developments in the transparent-chamber technique as adapted to the mouse. J Natl Cancer Inst (1949) 1.19
Intravital imaging of stromal cell dynamics in tumors. Curr Opin Genet Dev (2009) 1.16
The color of mice: in the light of GFP-variant reporters. Histochem Cell Biol (2001) 1.14
Behavior of immune players in the tumor microenvironment. Curr Opin Oncol (2009) 1.11
The many roads to cross-presentation. J Exp Med (2005) 1.08
Solid tumors "melt" from the inside after successful CD8 T cell attack. Eur J Immunol (2006) 1.02
Fas expression by tumor stroma is required for cancer eradication. Proc Natl Acad Sci U S A (2013) 0.95
Cytotoxic immunological synapses do not restrict the action of interferon-γ to antigenic target cells. Proc Natl Acad Sci U S A (2012) 0.91
Targeting the tumour stroma to increase efficacy of chemo- and radiotherapy. Clin Transl Oncol (2009) 0.90
Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis. Int J Cancer (2010) 0.88
Antigenic cancer cells that escape immune destruction are stimulated by host cells. Cancer Res (1995) 0.87
The role of the antigen-presenting cell in Fas-mediated direct and bystander killing: potential in vivo function of Fas in experimental allergic encephalomyelitis. J Immunol (1999) 0.85
Intravital imaging of anti-tumor immune response and the tumor microenvironment. Semin Immunopathol (2010) 0.83
Multiphoton imaging of cytotoxic T lymphocyte-mediated antitumor immune responses. Curr Top Microbiol Immunol (2009) 0.80
Stromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in mice. PLoS One (2012) 0.79
Rethinking the role of myeloid-derived suppressor cells in adoptive T-cell therapy for cancer. Oncoimmunology (2014) 0.75